Protalea Bio

Creating therapies for prolonging healthy life

Our mission

The therapeutics of the future will be preventative

Protalea Bio’s therapeutic antibodies can prevent certain age-associated cancers and neuroinflammation earlier than existing treatments, thereby prolonging healthy life.

Protalea Bio is developing first-in-class treatments that halt the progression of cancer and neurodegeneration We do this by targeting pre-disease inflammation before the disease has a chance to develop

Our Approach

Insights from Gaucher disease can prevent cancer and neurodegeneration

Glycosphingolipids (GSLs):

An essential part of the cell membrane and needed for regular cell function

A disruption of GSL degradation causes inflammation across different organ systems

Severe disruption of GSL degradation causes Gaucher Disease

Less severe mutations still significantly raise cancer and neurodegeneration risk in parts of the ageing population

Protalea therapeutics tackle GSL-related inflammation before it has a chance to cause a disease state

Our Expertise

Blue outline of a microscope

There is not yet anything anyone can do to prevent MGUS from progressing to myeloma. The core challenges of treating myeloma early is its detection at an early stage.

Building on a decade of research in lysosomal diseases and cancer, we are developing a novel and disruptive approach to rational cancer prevention discovery.

An elderly man smiling as a healthcare worker places a hand on his shoulder during a vaccination.

Our unique expertise in lysosomal pathology and sphingolipid biology that has been shaped by decades of research into sphingolipidoses - group of rare inherited metabolic disorders and the key discovery of a causal link between Gaucher and lymphoid cancers and autoinflammation.

Who we are

Dr Elena Pavlova is a clinician and research scientist developing a new preventive treatment for blood and liver cancers based on more than 15 years of research in Cambridge University. Elena’s experimental studies have revealed new insights into association of autoimmunity and Gaucher disease.